Patents by Inventor Raymond Chavez
Raymond Chavez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230203053Abstract: The present invention encompasses improved morphian compositions and methods of use of the improved compositions for modulating neuropathic pain, opioid-induced glial activation, or a combination thereof beyond what is currently known in the art. The methods involve administering the compound of Formula I to a subject.Type: ApplicationFiled: October 7, 2022Publication date: June 29, 2023Applicant: Xalud Therapeutics, Inc.Inventors: Raymond A. Chavez, Stephen Collins
-
Publication number: 20230158114Abstract: This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.Type: ApplicationFiled: January 25, 2023Publication date: May 25, 2023Applicants: Xalud Therapeutics, Inc., The Regents of the University of Colorado, a Body CorporateInventors: Raymond A. Chavez, Linda May Rothblum Watkins, Robert Landry
-
Patent number: 11505556Abstract: The present invention encompasses improved morphian compositions and methods of use of the improved compositions for modulating neuropathic pain, opioid-induced glial activation, or a combination thereof beyond what is currently known in the art. The methods involve administering the compound of Formula I to a subject.Type: GrantFiled: December 12, 2018Date of Patent: November 22, 2022Assignee: Xalud Therapeutics, Inc.Inventors: Raymond A. Chavez, Stephen Collins
-
Publication number: 20220313785Abstract: This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.Type: ApplicationFiled: June 21, 2022Publication date: October 6, 2022Applicants: Xalud Therapeutics, Inc., The Regents of the University of Colorado, a Body CorporateInventors: Raymond A. Chavez, Linda May Rothblum Watkins, Robert Landry
-
Publication number: 20210087202Abstract: The present invention encompasses improved morphian compositions and methods of use of the improved compositions for modulating neuropathic pain, opioid-induced glial activation, or a combination thereof beyond what is currently known in the art. The methods involve administering the compound of Formula I to a subject.Type: ApplicationFiled: December 12, 2018Publication date: March 25, 2021Applicant: Xalud Therapeutics, Inc.Inventors: Raymond A. Chavez, Stephen Collins
-
Publication number: 20200093892Abstract: This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.Type: ApplicationFiled: October 31, 2019Publication date: March 26, 2020Applicants: Xalud Therapeutics, Inc., The Regents of the University of Colorado, a Body CorporateInventors: Raymond A. Chavez, Linda May Rothblum Watkins, Robert Landry
-
Patent number: 10512672Abstract: This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.Type: GrantFiled: July 17, 2014Date of Patent: December 24, 2019Assignees: Xalud Therapeutics, Inc., The Regents of the University of Colorado, a Body CorporateInventors: Raymond A. Chavez, Linda R. Watkins, Robert Landry
-
Publication number: 20190112354Abstract: This invention relates to methods and compositions for overcoming the dose-dependent down regulation of interleukin 10 (IL-10) by expressing, in addition to an interleukin 10 (IL-10) peptide, an IL-10 receptor type 1 (IL-10R1) peptide. The methods have use in treating a variety of diseases and symptoms, including but not limited to neuropathic or chronic pain; symptoms and physiological damage associated with multiple sclerosis, spinal cord injury, ALS, neuroinflammation, arthritis and other diseases of the joint; and autoimmune diseases.Type: ApplicationFiled: April 21, 2017Publication date: April 18, 2019Inventors: John Forsayeth, Raymond Chavez, Linda Watkins, Peter Grace
-
Publication number: 20160235816Abstract: This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.Type: ApplicationFiled: July 17, 2014Publication date: August 18, 2016Inventors: Raymond A. CHAVEZ, Linda R. WATKINS, Robert LANDRY
-
Publication number: 20130337556Abstract: Methods of delivering transgenes to target cells using plasmids comprising viral inverted terminal repeat (ITR) sequences are described. Such plasmids are capable of directing sustained transgene expression in target cells in rats provided that at least one adeno-associated virus (AAV) ITR sequence is present in the plasmid, regardless of whether that ITR is located upstream or downstream of the transgene. In a particular embodiment, plasmids comprising one or more AAV ITR sequence and an IL-10 transgene are shown to be effective in sustained reversal of pain in an animal model of neuropathic pain.Type: ApplicationFiled: July 23, 2013Publication date: December 19, 2013Applicant: The Regents of the University of Colorado, a body corporateInventors: Linda Watkins, Travis Hughes, Raymond Chavez
-
Patent number: 8524678Abstract: Methods of delivering transgenes to target cells using plasmids comprising viral inverted terminal repeat (ITR) sequences are described. Such plasmids are capable of directing sustained transgene expression in target cells in rats provided that at least one adeno-associated virus (AAV) ITR sequence is present in the plasmid, regardless of whether that ITR is located upstream or downstream of the transgene. In a particular embodiment, plasmids comprising one or more AAV ITR sequence and an IL-10 transgene are shown to be effective in sustained reversal of pain in an animal model of neuropathic pain.Type: GrantFiled: May 26, 2006Date of Patent: September 3, 2013Assignee: The Regents of the University of Colorado, a body corporateInventors: Linda May Rothblum Watkins, Travis Hughes, Raymond A. Chavez
-
Publication number: 20110306559Abstract: Compositions and methods for the treatment of neuropathic pain are provided. Compositions of the invention may comprise proteins with a zinc-finger domain fused to a regulatory domain that is capable of either activating or repressing the expression of a target gene involved in neuropathic pain. Alternatively, compositions of the invention may comprise a nucleic acid sequence encoding a protein of the invention, which nucleic acid sequence may optionally be provided as a plasmid or within a virus or other vector for delivery to a target cell or tissue. Methods of treating neuropathic pain involving treatment of subject with the compositions of the invention are also provided. Exemplary target genes for the treatment of neuropathic pain include VR1, NaV1.8, and TrkA.Type: ApplicationFiled: December 23, 2009Publication date: December 15, 2011Applicant: SANGAMO BIOSCIENCES, INC.Inventors: John R.M. Forsayeth, Raymond A. Chavez, Trevor N. Collingwood
-
Patent number: 7749490Abstract: IL-10 sequence variants are disclosed that retain the therapeutically desirable anti-inflammatory properties of wild-type IL-10 but do not retain the hemoatopoeitic cell regulatory and cell proliferative activities. The mutant IL-10 polypeptides of the invention are used in methods of treating diseases involving inflammatory response, including neuropathic pain and other neurological disorders.Type: GrantFiled: May 26, 2006Date of Patent: July 6, 2010Assignee: The Regents of the University of ColoradoInventors: Jurg M. Sommer, Raymond A. Chavez, Kirk W. Johnson, Linda May Rothblum Watkins
-
Publication number: 20100028296Abstract: Peptides derived from anti-inflammatory cytokines, such as IL-10, are disclosed for use in treatment of neurodegenerative diseases and neuropathic pain indications, including Alzheimer's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease and trigeminal neuralgia.Type: ApplicationFiled: May 1, 2006Publication date: February 4, 2010Inventors: Raymond A. Chavez, Kirk W. Johnson, Jennifer Shumilla, Laura Sanftner
-
Publication number: 20090208563Abstract: Methods of delivering transgenes to target cells using plasmids comprising viral inverted terminal repeat (ITR) sequences are described. Such plasmids are capable of directing sustained transgene expression in target cells in rats provided that at least one adeno-associated virus (AAV) ITR sequence is present in the plasmid, regardless of whether that ITR is located upstream or downstream of the transgene. In a particular embodiment, plasmids comprising one or more AAV ITR sequence and an IL-10 transgene are shown to be effective in sustained reversal of pain in an animal model of neuropathic pain.Type: ApplicationFiled: May 26, 2006Publication date: August 20, 2009Inventors: Linda May Rothblum Watkins, Travis Hughes, Raymond A. Chavez
-
Publication number: 20090035256Abstract: IL-10 sequence variants are disclosed that retain the therapeutically desirable anti-inflammatory properties of wild-type IL-10 but do not retain the hemoatopoeitic cell regulatory and cell proliferative activities. The mutant IL-10 polypeptides of the invention are used in methods of treating diseases involving inflammatory response, including neuropathic pain and other neurological disorders.Type: ApplicationFiled: May 26, 2006Publication date: February 5, 2009Inventors: Jurg M. Sommer, Raymond A. Chavez, Kirk W. Johnson, Linda May Rothblum Watkins
-
Publication number: 20060040880Abstract: Compositions and methods for the treatment of neuropathic pain are provided. Compositions of the invention may comprise proteins with a zinc-finger domain fused to a regulatory domain that is capable of either activating or repressing the expression of a target gene involved in neuropathic pain. Alternatively, compositions of the invention may comprise a nucleic acid sequence encoding a protein of the invention, which nucleic acid sequence may optionally be provided as a plasmid or within a virus or other vector for delivery to a target cell or tissue. Methods of treating neuropathic pain involving treatment of subject with the compositions of the invention are also provided. Exemplary target genes for the treatment of neuropathic pain include VR1, NaV1.8, and TrkA.Type: ApplicationFiled: April 8, 2005Publication date: February 23, 2006Inventors: John Forsayeth, Raymond Chavez, Trevor Collingwood, Andrew McNamara, Yann Jouvenot
-
Patent number: 6610827Abstract: The present invention provides novel potassium channel subunits (denoted Kv-SL1 and Kv-SL2, and collectively as Kv-SL) and polynucleotides which identify and encode them. The invention also provides expression vectors and host cells comprising nucleic acid sequence encoding Kv-SL. The invention also provides antibodies of Kv-SL and methods of diagnosing and treating diseases associated with expression of Kv-SL, and screening assays employing the protein, nucleotide, and antibody compositions.Type: GrantFiled: October 28, 1998Date of Patent: August 26, 2003Assignee: Elan Pharmaceuticals, Inc.Inventors: John R. Forsayeth, Byron Zhao, Raymond A. Chavez